ArticleCase reports in dermatological medicine2025
Amyopathic Dermatomyositis in a Patient With Breast Cancer in Remission: A Case Report and a Systematic Review of the Literature.
Article in Case reports in dermatological medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amyopathic dermatomyositis is a rare inflammatory disease in the spectrum of dermatomyositis characterized by typical skin lesions in the absence of muscle involvement. Dermatomyositis is a well-known paraneoplastic syndrome that can reveal or indicate a relapse of an underlying malignancy. To our knowledge, only a few cases of amyopathic dermatomyositis associated with breast cancer have been described in the literature. Here, we describe the case of a 52-year-old female with known triple-negative breast cancer in remission presenting with amyopathic dermatomyositis with a good response to hydroxychloroquine, and we performed a systematic review of this disease association. These patients should be followed closely for skin manifestations recurrence, therefore cancer recurrence or a new malignancy diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.